Amr Abdelkareem

Dr. Amr Abdelkareem

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Women's Health
Verified
Journal Article
Closed access
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy
MAMohamed Y. Abdel-Rahman
Mohamed Y. Abdel-Rahman
JTJustin Tan
Justin Tan
FAFaten F. AbdelHafez
Faten F. AbdelHafez
AAAmr Abdelkareem
Amr Abdelkareem
JLJames H. Liu
James H. Liu
Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive age women, yet its clinical presentation shares similarities with several other endocrine disorders such as thyroid disease. Hence, the objective of this study was to further evaluate this association by investigating the clinical, hormonal, and metabolic parameters between subclinical hypothyroidism (SCH) and PCOS. Methods: This is a cross-sectional study conducted in a tertiary care clinic at Cleveland, Ohio, USA. A total of 137 women diagnosed with PCOS by Rotterdam criteria were examined. SCH was defined as thyroid-stimulating hormone >2.5 mIU/L in the absence of symptoms of overt hypothyroidism. The mean age, body mass index (BMI), fasting plasma glucose (FPG), glucose tolerance test, hemoglobin A1c, fasting insulin, a 2 hours insulin level after 75 g glucose load, cholesterol, LDL, HDL, and homeostatic model assessment (HOMA) were compared between women with and without SCH. Logistic regression was used to adjust for age and BMI. Results: Among 137 women with PCOS, 21.9% had SCH. Comparison groups were similar in both age and BMI and there was no difference in the mean values of all endocrine and metabolic parameters tested. However, abnormal FPG levels (OR 3.01; CI: 1.12–8.07. p = 0.03) and abnormal HOMA (OR 3.7; CI: 1.14–12.00. p = 0.03) were more likely in women who had SCH than in women without SCH independent of age and BMI. Conclusions: Women with PCOS and SCH are more likely to have impaired FPG values and impaired insulin sensitivity even after adjusting for age and BMI. Hence, close monitoring of PCOS patients for SCH may be beneficial.

17 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FAFahad Alotaibi
Fahad Alotaibi
BPBo Peng
Bo Peng
CKChristian Klausen
Christian Klausen
ALAnna Lee
Anna Lee
AAAmr Abdelkareem
Amr Abdelkareem
PYPaul Yong
Paul Yong
Deep infiltrating endometriosis (DIE) is defined as an endometriotic lesion penetrating to a depth of >5 mm and is associated with pelvic pain, but the underlying mechanisms are unclear. Our objective is to investigate whether plasminogen activator inhibitor-1 expression (PAI-1) in endometriotic tissues is increased in women with DIE. In this blinded in vitro study, immunohistochemistry and Histoscore were used to examine the expression of PAI-1 in glandular epithelium (GECs) and stroma (SCs) in a total of 62 women: deep infiltrating uterosacral/rectovaginal endometriosis (DIE; n = 13), ovarian endometrioma (OMA; n = 14), superficial peritoneal uterosacral/cul-de-sac endometriosis (SUP; n = 23), uterine (eutopic) endometrium from women with endometriosis (UE; n = 6), and non-endometriosis eutopic endometrium (UC; n = 6). The following patient characteristics were also collected: age, American Fertility Society stage, hormonal suppression, phase of menstrual cycle, dysmenorrhea score and deep dyspareunia score. PAI-1 expression in GECs and SCs of the DIE group was significantly higher than that of SUP group (p = 0.01, p = 0.01, respectively) and UE group (p = 0.03, p = 0.04, respectively). Interestingly, increased PAI-1 expression in GECs and SCs was also significantly correlated with increased dysmenorrhea (r = 0.38, p = 0.01; r = 0.34, p = 0.02, respectively). We found higher expression of PAI-1 in DIE, and an association between PAI-1 and worse dysmenorrhea.

6 March 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy
BFBahi Fayek
Bahi Fayek
EYEmily C Yang
Emily C Yang
MIMahmoud S Iews
Mahmoud S Iews
Mohamed ElgendiMohamed Elgendi
Mohamed Elgendi
FHFaten F Abdel Hafez
Faten F Abdel Hafez
Does the occurrence of non-visualized pregnancy loss (NVPL) affect future reproductive outcomes in patients with recurrent pregnancy loss (RPL)? The number of previous NVPLs is a significant predictor of subsequent live birth in patients with RPL. The number of preceding miscarriages is a strong indicator for future reproductive outcomes. However, NVPL particularly has been sparsely addressed in previous literature. We performed a retrospective cohort study of 1981 patients attending a specialized recurrent pregnancy loss clinic (RPL) from January 2012 to March 2021. A total of 1859 patients met the inclusion criteria of the study and were included in the analysis. Patients with a history of RPL, defined as ≥2 pregnancy losses before 20 weeks gestation, who attended a specialized RPL clinic in a tertiary care center were included. Patients’ evaluation included parental karyotyping, antiphospholipid antibodies screening, uterine cavity assessment with hysterosalpingography (HSG) or hysteroscopy, maternal thyroid stimulating hormone (TSH) testing, and serum hemoglobin A1C testing. Other investigations were performed only when indicated such as testing for inherited thrombophilias, serum prolactin, oral glucose tolerance test, and endometrial biopsy. Patients were divided into three groups; patients who experienced NVPLs only (pure NVPLs group), patients with only visualized pregnancy losses (pure VPLs group), and patients with history of both NVPLs and VPLs (mixed group). Statistical analysis was performed using Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables. Significance was detected when P values <0.05. A logistic regression model was used to determine the impact of NVPLs and VPLs numbers on any live birth subsequent to the initial RPL clinic visit. The prevalence of patients with pure NVPLs, pure VPLs, and mixed losses was 14.7% (274/1859), 31.8% (591/1859), and 53.5% (994/1859), respectively. The prevalence of acquired and congenital uterine anomalies diagnosed by HSG or hysteroscopy was significantly different between pure NVPLs, pure VPLs, and mixed groups (16.8% versus 23.7% versus. 20.7%, respectively P = 0.05). There were no significant differences in the results of other RPL investigations or baseline demographics between the three groups. A logistic regression model controlling for maternal age at the initial RPL clinic visit and the follow-up duration showed that the numbers of NVPLs (odds ratio (OR): 0.77, CI: 0.68–0.88) and VPLs (OR: 0.75, CI: 0.64–0.86) are strong predictors for subsequent live births after the initial RPL clinic visit (P < 0.001). The odds of having a live birth decreased by 23% and 25% with each additional NVPL and VPL, respectively. This study may be limited by its retrospective design. Some of our data, including home pregnancy tests and obstetric history, are based on patient self-reporting, which could have overstated the true prevalence of NVPLs. Another limitation is the lack of available live birth data for all patients at the time of the analysis. To our knowledge, this is the first study to examine and analyze the reproductive outcomes of patients with pure NVPLs in a substantial cohort of patients with RPL. NVPLs seem to affect future live births the same way as clinical miscarriages, which supports their inclusion in RPL definitions. This study was supported in part by Canadian Institute Heath Grant (CIHR): Reference Number/W11-179912 and Women's Health Research Institute (WHRI), Vancouver, BC, Canada. M.A.B: Research grants from Canadian Institute for Health Research (CIHR) and Ferring Pharmaceutical. M.A.B. is on the advisory board for AbbVie and Baxter. N/A.

1 April 2020 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
GLGeneviève Leduc-Robert
Geneviève Leduc-Robert
MIMahmoud Iews
Mahmoud Iews
AAAmr Abdelkareem
Amr Abdelkareem
CWChristina Williams
Christina Williams
DBDena Bloomenthal
Dena Bloomenthal
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy

18 February 2020 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
AAAmr Abdelkareem
Amr Abdelkareem
FAFahad T. Alotaibi
Fahad T. Alotaibi
GAGhadeer M. AlKusayer
Ghadeer M. AlKusayer
AAAbdou S. Ait-Allah
Abdou S. Ait-Allah
SRSalah M. Rasheed
Salah M. Rasheed
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy

13 October 2022 in F&S Science
Verified
Journal Article
Closed access
AAAmr Abdelkareem
Amr Abdelkareem
SGSahar Mohamed Gebril
Sahar Mohamed Gebril
FAFaten F. AbdelHafez
Faten F. AbdelHafez
JTJefferson Terry
Jefferson Terry
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy